ArticleSubstance abuse2020
The use of off-label medications in substance abuse treatment programs.
Article in Substance abuse, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 7 citations in OpenAlex.
- Harm reduction and pharmacy practice: a scoping review of services for people who use drugs provided by pharmacy staff.BMJ open · 2026Article
- Informed consent and contraception when prescribing valproate to individuals of childbearing potential: a quality improvement project.Archives of women's mental health · 2026Article
- Off-label and investigational drugs in the treatment of gambling disorder: a critical review.Frontiers in pharmacology · 2026Review
- Identifying compounds to treat opiate use disorder by leveraging multi-omic data integration and multiple drug repurposing databases.Translational psychiatry · 2025Article
- Animal models of cocaine use: importance of social context and co-use.Trends in pharmacological sciences · 2025Review
- Feasibility of using real-world data to emulate substance use disorder clinical trials: a cross-sectional study.BMC medical research methodology · 2024Article
- Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.